￡6m for Cambridge spin-out

摘要

A Cambridge-based spin-out company will be translating cutting-edge cell biology research on DNA repair into drugs to improve the management of life-threatening diseases like cancer.A team led by Professor Stephen Jackson - together with Cancer Research Technology and the University of Cambridge - have launched Mission Therapeutics. The company has raised ￡6m in Series A funding from a syndicate led by Sofmnova Partners.